IRCT201104052515N3Completed未知
The effect of omega- 3 on quality of life,menopausal sumptoms and sextual dysfunction in tamoxifen consumer women with breast cancer that refer to motahhari breast cancer clinic in 1390
Vice chancellor for research, shiraz university of medical science0 sites140 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 140
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- no limit to 50 years (—)
- Sex
- Female
Inclusion Criteria
- •Medical record review identified female patients who were initially diagnosed as stage 1 and 2 with breast cancer prior to menopause age or menopause are not related to medication or surgery, married, be literate, signed and confirmed consent form, completed adjuvant treatment such as chemotherapy, hormonal therapy with tamoxifen or suffered by tamoxifen treatment side effects such as; hot flashes, sexual dysfunction, night sweats, negative impact on life quality, that met the inclusion criteria.
- •After deletion of patients who met specific exclusion criteria such as; high blood pressure, blood lipids, renal and thyroid dysfunction, history of allergy to O-3, using medication or food complementary for the purpose of preventing or reducing complications and/or side effects of tamoxifen treatment, using medication to treat mental disorder, having sever and progressive disease(s), disease relapsation, those patients who were initially or latelly diagnosed with advanced stages (>2) of breast cancer and finally those one unwillingness to continue participation in research.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Not Applicable
Weight loss and omega 3Obesity.Obesity, unspecifiedIRCT201504267903N4Deputy of Chancellor for Research of Tehran University of Medical Sciences50
Completed
Phase 2
The effect of omega 3 polyunsaturated fatty acid supplementation on inflammatory markers and insulin resistanse factors in patients with Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseCondition 1: type 2 diabetes. Condition 2: Nonalcoholic fatty liver disease (NAFLD).Non-insulin-dependent diabetes mellitusFatty (change of) liver, not elsewhere classified (NAFLD)IRCT2017103030489N2Yazd Shahid Sadoughi University of Medical Sciences48
Completed
Phase 2
Effect of omega-3 fatty acid supplementation in patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.Condition 1: type 2 diabetes. Condition 2: Nonalcoholic fatty liver disease (NAFLD).Non-insulin-dependent diabetes mellitusFatty (change of) liver, not elsewhere classified (NAFLD)IRCT2016102530489N1Yazd Shahid Sadoughi University of Medical Sciences60
Completed
Phase 2
Effects omega-3 fatty acid supplementation in the treatment of diabetesDiabetic nephropathy.Insulin-dependent diabetes mellitusIRCT201502255623N36Kashan University of Medical Sciences60
Recruiting
Phase 3
Omega-3 on vascular function in hemodialysis patientsEnd stage renal disease (ESRD).End stage renal diseaseN18.6IRCT20220611055142N1Tabriz University of Medical Sciences36